Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials

April 20, 2023

(BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to
treat COVID-19 and other viral diseases, announced that its long awaited Acelluar Oxygen
Carrier BXT-25 has been successfully tested in animals. The initial results are very
encouraging because they show the non-toxicity of the experimental drug, along with the
corresponding full recovery in Swiss Albino mice, in an experiment carried out in a joint
venture with NDPD Pharma, Inc. As a next step, the Company intends to proceed with a 14-
day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats as
funding permits.

The animal protocol used on the Swiss Albino mice hemorrhaged 20% of the animal’s blood
which normally increases heart and respiratory rates. The fact that none of the treated
animals experienced any symptoms is a huge testament to the potential efficacy of the
experimental oxygen transport molecule. Reading into the data a little more, revealed that
the mice fully recovered because their bodies were able to replenish the lost blood as BXT-
25 was metabolized by the animal.

This breakthrough opens up the possibility of creating one of the largest platform drugs in
existence. Since BXT-25 is 5,000 times smaller than a blood cell, it has the ability to
permeate hypoxic regions of the body’s organs where the vasculature doesn’t support good
blood flow. Many familiar with Hyperbaric Oxygen Treatment (HBOT) could think of BXT-25
as the intravenous version of HBOT treatment that lasts 9-18 hours and without any harmful
side effects. HBOT treatment typically lasts no more than 1.25 hours daily, due to the risks
of side effects. The platform drug was designed to be non-toxic and target both hypoxia and
degenerative diseases. The company expects BXT-25 will represent a new paradigm in the
way strokes and neurodegenerative diseases such as Alzheimer’s, Dementia, and
Traumatic Brain Injury are treated. Other indications like ARDS, Sickle Cell Anemia, and
Wound healing are some diverse indications that could benefit from BXT-25. The company
also has an exclusive license to use the MDX viewer in clinical trials. The MDX viewer is
FDA Approved, with a 510-K label to measure the level of hypoxia in cells.

About BXT-25

BXT-25, will be tested as a potent resuscitative agent to treat cerebrovascular accidents.
The product is based on a new molecule reversing hypoxia in areas have limited access,
originally developed for cerebral contrast imaging. The company plans to submit an
Investigational New Drug Application to the Food and Drug Administration (FDA) and enter
into clinical trials on stroke patients.

Initial non-clinical studies on animals indicated positive results:

•No nitric oxide scavenging (absence of increased blood pressure)
•No animal toxicity.
•Oxygen delivery to hypoxic cells

Th Company’s objective is to conduct proof of concept clinical trials for safety and efficacy
of BXT-25 and enter into business relations with several large drug companies.

About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies
targeting the treatment of significant unmet medical needs in virology, degenerative
disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral
drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant
diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke
treatment. More information can be found at

Investor Relations
Michael Sheikh


Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law,
including those related to the performance of technology described in this press release.
These forward-looking statements are generally identified by the words “believe,” “expect,”
“anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-
looking statements contain these identifying words. Such statements are subject to
significant risks, assumptions and uncertainties. Known material factors that could cause
Bioxytran’s actual results to differ materially from the results contemplated by such forward-
looking statements are described in the forward-looking statements and risk factors in the
Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and
those risk factors set forth from time-to-time in other filings with the Securities and
Exchange Commission. Bioxytran undertakes no obligation to correct or update any
forward-looking statement, whether as a result of new information, future events, or
otherwise, except to the extent required under federal securities laws.